Forest Laboratories, Inc. and Tropon GmbH signed a manufacturing agreement for the production and packaging of a solid, oral antibiotic based on faropenem medoxomil at Tropon’s Cologne manufacturing plant. This antibiotic is currently under review by the FDA. Forest Labs will use Tropon’s manufacturing capabilities for the U.S. markets with the licence holder for the product, Replidyne Inc. Tropon has worked with Replidyne on the commercialization of this product for the past two...